Cybin Inc. CEO to Showcase Next-Gen Mental Health Treatments at Canaccord Genuity Growth Conference

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a leader in the development of next-generation mental health treatments, has announced that its CEO, Doug Drysdale, will participate in a fireside chat at the upcoming Canaccord Genuity 45th Annual Growth Conference. Scheduled for August 12, 2025, in Boston, this event will spotlight Cybin's pioneering work in neuropsychiatry, particularly its efforts to revolutionize mental healthcare through innovative treatments.

The conference will feature a live webcast at 2:30 p.m. ET, offering investors and the public an opportunity to gain insights into Cybin's groundbreaking research and development pipeline. An archived version of the webcast will be made available on Cybin's investor relations site, ensuring broader access to this valuable information. For more details on the announcement, visit https://ibn.fm/6xavA.

Cybin is at the forefront of addressing the significant unmet needs in mental health care, with a focus on developing treatments that offer long-lasting results through intermittent dosing. The company's current pipeline includes CYB003, a deuterated psilocin analog in Phase 3 studies for major depressive disorder, and CYB004, a deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder. These investigational compounds represent a new wave of potential treatments targeting 5-HT receptors, offering hope for millions suffering from mental health conditions.

Founded in 2019, Cybin has rapidly expanded its operations across Canada, the United States, the United Kingdom, the Netherlands, and Ireland, demonstrating its commitment to global mental health innovation. The company's participation in the Canaccord Genuity Growth Conference underscores its leadership in the neuropsychiatry sector and its dedication to transforming mental healthcare. For further information on Cybin's developments, visit https://ibn.fm/CYBN.